C90.02
C90.02 — Multiple myeloma in relapse
Billable / specific codeICD-10-CM
C90.02 is a billable, specific ICD-10-CM code for multiple myeloma in relapse. It is valid for submission on a claim.
Risk adjustment
C90.02 risk-adjusts. Under the CMS-HCC V28 model it maps to this category:
- HCC 19 Myelodysplastic Syndromes, Multiple Myeloma, and Other Cancers1.798 RAF
Coefficient shown for the Community Non-dual Aged segment. A higher HCC in the same hierarchy will suppress this one, so capturing it does not always add score.
Medicare coverage
C90.02 is named in 69 Medicare coverage policies — 69 listing it as supporting medical necessity. Which of them applies to you depends on your Medicare contractor, and coverage genuinely differs by state.
- A52399Billing and Coding: Denosumab (Prolia®, Xgeva®, Jubbonti®, Wyost®, Ospomyv™,Xbryk™,Bomyntra®, Conexxence®, Stoboclo®, Osenvelt®,Bildyos®, Bilprevda®)
- A52450Billing and Coding: Paclitaxel (e.g., Taxol®/Abraxane ™)
- A52479Oral Anticancer Drugs - Policy Article
- A52479Oral Anticancer Drugs - Policy Article
Related codes at this level
Codes that share C90.0. If C90.02 is not quite right, the correct code is usually one of these.
Questions about C90.02
- Is C90.02 a billable ICD-10-CM code?
- Yes. C90.02 is a billable, specific ICD-10-CM code and is valid for submission on a claim.
- Where does C90.02 sit in the tabular list?
- Neoplasms (C00-D49), in the block Malignant neoplasms of lymphoid, hematopoietic and related tissue (C81-C96).